High-grade gliomas: reality and hopes. by Mirimanoff, R.O.
High-grade gliomas: reality and hopes
Editorial
Chinese Journal of Cancer
Author′s Affiliations: 1Department of Radiation Oncology, Clinique de La 
Source, Lausanne CH-1004, Switzerland; 2Faculty of Biology and Medicine, 
University of Lausanne, Clinique de La Source, Lausanne CH-1004, 
Switzerland.
Corresponding Author: René-Olivier Mirimanoff, Department of 
Radiation Oncology, Clinique de La Source, Avenue Vinet 30, Lausanne 





      In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and 
future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, 
the progress has been impressive. For example, discoveries at the molecular level have already impacted 
imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing 
role in the management of these cancers. The European Organization for Research and Treatment of 
Cancer (EORTC) has pioneered new treatment strategies and contributed to new standards. The articles 
in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, 
innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or 
combined with chemotherapy, current standards and novel approaches for systemic treatments, and the 
important but often neglected field of health-related quality of life. Despite the advances described in these 
articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more 
research is needed to address this problem.
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      Among more than 100 different histological subgroups of brain 
tumors, high-grade gliomas (HGG) are the most frequent entities, 
accounting for over 50% of primary malignant brain tumors, 
depending on age and country. The incidence of HGG has increased 
in past decades and has become quite significant in the older 
population. In spite of recent important advances in understanding 
basic molecular mechanisms of HGG, spectacular improvements 
in imaging, surgery, and radiotherapy, as well as the discovery of 
a series of new promising drugs and targeted agents, the overall 
prognosis remains poor, with a few exceptions. In the past, a 
common mistake was to include all HGG in the same tumor category, 
for example, WHO grade 3 and grade 4 tumors were included 
in the same treatment or research protocols, despite that their 
characteristics and prognoses are widely different. On histopathologic 
assessment, grade 4 gliomas or glioblastoma multiforme (GBM) 
present features like necrosis and intense microvascular proliferation, 
which are not found in grade 3 anaplastic astrocytoma (AA) or 
anaplastic oligodendriglioma (AO). Furthermore, AO exhibits cells 
with a characteristic “fried-egg” appearance, which is not found 
in pure AA. In addition different tumor subtypes show distinct 
cytogenetic abnomalities, some of which are critically important for 
their diagnostic, prognostic, and predictive values. Examples include 
the O-6-methylguanine-DNA methyltransferase (MGMT) methylation, 
epidermal growth factor receptor (EGFR) amplification, and vascular 
endothelial growth factor-A (VEGF-A) overexpression in GBM, or the 
1p/19q chromosomal co-deletion in AO. Sequential accumulation of 
genetic aberrations, deregulation of growth factor signaling pathways, 
and other genetic abnomalities are postulated to contribute to a 
continuum from low-grade (grade 2) to high-grade (grade 4) glioma. 
In practice, however, only 10% of GBMs develop from grade 2 
gliomas, and currently, the management of the former does not differ 
from that of “spontaneous” GBM. As will be seen in this issue of the 
Chinese Journal of Cancer dedicated to HGG, the progress made 
in the basic biological understanding of these tumors has impacted 
not only systemic treatments but also the newest imaging modalities, 
surgical management, and radiotherapy planning and delivery. 
Currently, the treatment backbone of HGG almost always includes 
surgery, radiotherapy, and chemotherapy. The pivotal European 
Organization for Research and Treatment of Cancer-National Cancer 
Institute of Canada (EORTC-NCIC) trial published in 2005 and 
updated in 2009 has established the standard treatment for GBM[1,2]. 
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Although a significant minority of patients can survive for several 
years[3,4], a majority will succomb to the disease. Progress has also 
been made in AA and AO[5,6], for which the prognosis is less gloomy; 
however intensive research is needed and important trials are 
ongoing[7,8]. Health-related quality of life (HRQoL) is a tool of growing 
importance in HGG[9,10]. It should be included in any prospective trial 
to aid clinicians in making final treatment decisions.
      In this issue, we have gathered a series of comprehensive 
reviews on different aspects of HGG. These articles have been 
written by European experts who are heavily involved in clinical 
research on HGG, most being major contributors of the EORTC Brain 
Tumor Group and Radiation Oncology Group.
      Hofer et al.[11] provide a clear and practical guide for clinicians, 
looking at the role of molecular markers in the diagnosis and 
treatment of HGG. Currently, 1p/19q chromosomal co-deletion, 
MGMT methylation, and IDH mutations have made their way into 
clinical practice, and a growing number of other markers are under 
investigation.
      Wolbers[12] describes surgery of HGG with the newest 
developments in preoperative planning, multimodal neuronavigation, 
and different means to allow safe and maximal cytoreduction, the 
latter associates with improved prognosis. Intraoperative imaging 
by fluorescence guidance seems to be particularly promising in 
this regard, and newer developments like implantable telemetric 
light or probes are being tested. Future and exciting developments 
include direct infusion of biological agents and transfer of genetic 
material into the tumor using various vectors, as well as other novel 
approaches.
      Radiotherapy plays a central role in the treatment of HGG, 
and has undergone important advances due to rapid progress in 
informatics, imaging, and the delivery of high-precision beams. 
Dhermain[13] reviews the current European and the US standards in 
radiotherapy planning and delivery and discusses their limitations. 
New concepts for planning should include judicious use of advanced 
imaging techniques to provide not only anatomic but also functional 
information on cellularity [diffusion magnetic resonance imaging 
(MRI)], angiogenesis (perfusion MRI) metabolic activity (positron 
emission tomography (PET), cellular proliferation [magnetic 
resonance spectroscopy (MRS)], and so on. Co-registration of these 
imaging techniques is essential but there are a number of drawbacks, 
highlighting the need for a better standardization. These imaging 
tools should be aimed at more efficiently delivering “the right dose to 
the right target” and should take into account the challenging problem 
of tumor heterogeneity and focal areas of radio-resistance.
      Villà et al.[14] give a comprehensive overview of the major trials 
that have set the standards of care in GBM. Surprisingly, it appears 
that in spite of well conducted randomized controlled trials, a 
substantial proportion of patients have not yet been offered the best 
treatments. Randomized controlled trials have established the role of 
postoperative radiotherapy versus no radiotherapy, and the optimal 
radiotherapy dose, and have explored all sorts of radiotherapy 
fractionations. For example, in elderly patients, hypofractionation 
is as efficient as conventional fractionation and spares the patients 
significant treatment time. Chemotherapy and chemoradiation have 
also been tested in randomized controlled trials. Villa et al. [14] analyze 
the pivotal EORTC-NCIC trial, including the major role of MGMT. 
      Hottinger et al .[15] provide a critical analysis of the current 
standards of care and novel approaches in the management of GBM, 
from a medical oncology and neuro-oncology point of view. Starting 
from the published trials in adult patients (EORTC-NCIC) and in 
elderly patients, they carefully evaluate novel therapies. Regarding 
angiogenesis, targeting VEGF seemed to be a very attractive 
approach, given VEGF overexpression in GBM. However, two recent 
randomized controlled trials on primary GBM had disappointing 
results, raising a number of questions regarding the addition of 
VEGF to chemoradiation. Furthermore, inhibiting integrins with the 
drug cilengitide produced encouraging results in phase 2 studies, in 
particular for patients whose tumors exhibit MGMT methylation, but 
the efficacy of this approach was not confirmed in a large randomized 
controlled trial. Various agents directed against EGFR have been 
tested, but here again results were disappointing. Similarly, inhibitors 
of mTOR and protein kinase C did not produce desired effects. Still, 
a number of other novel approaches such as immunotherapy and 
alternating electric fields are being tested in randomized controlled 
trials, but clearly, further intensive research is needed.
      Finally, Dirven et al. [16] remind us that the recognition of palliation 
and improvement of the quality of life (QoL) are at least as important 
as overall survival or progression-free survival, especially in cancers 
with a poor prognosis like GBM. Health-related quality of life 
(HRQoL) is a concept that takes into account physical, psychologic, 
and social parameters and also includes symptoms induced by the 
disease and treatment. The EORTC has developed the QLQ-C30 
generic questionnaire for cancer patients and the QLQ-BN-20 brain 
tumor-specific questionnaire. Other groups have also developed 
questionnaires that are currently being used to assess HRQoL. 
Collectively, these questionnaires allow investigators to efficiently 
measure the effect on the disease as well as the impact of treatments 
like surgery, radiotherapy, and chemotherapy on QoL. For example, 
studies show that HRQoL scores decreased overall after surgery or 
radiotherapy, but other trials of chemotherapy and chemoradiation 
disclosed no negative effect or even a slight improvement. In their 
comprehensive analysis, Dirven et al .[16] remind us that in clinical 
trials, the benefits of a new treatment strategy should be carefully 
weighed against the side effects of the treatments, not only in terms 
of overall and progression-free survivals but also in terms of HRQoL. 
HRQoL is also expected to impact daily clinical decision-making and 
health care policy.
      In summary, many studies on HGG have been conducted and 
have improved the overall understanding and management of these 
malignant brain tumors, but overall prognosis remains rather poor 
and continuous and extensive research should be carried out.
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